Recent advances in the development of p21-activated kinase inhibitors

References

• Davis RJ. Signal transduction by the JNK group of MAP kinases. Cell 2000; 103:239 - 52; http://dx.doi.org/10.1016/S0092-8674(00)00116-1; PMID: 11057897
   PubMed Web of Science ®Google Scholar
• Jaffer ZM, Chernoff J. p21-activated kinases: three more join the Pak. Int J Biochem Cell Biol 2002; 34:713 - 7; http://dx.doi.org/10.1016/S1357-2725(01)00158-3; PMID: 11950587
   PubMed Web of Science ®Google Scholar
• Pirruccello M, Sondermann H, Pelton JG, Pellicena P, Hoelz A, Chernoff J, et al. A dimeric kinase assembly underlying autophosphorylation in the p21 activated kinases. J Mol Biol 2006; 361:312 - 26; http://dx.doi.org/10.1016/j.jmb.2006.06.017; PMID: 16837009
   PubMed Web of Science ®Google Scholar
• Baskaran Y, Ng YW, Selamat W, Ling FT, Manser E. Group I and II mammalian PAKs have different modes of activation by Cdc42. EMBO Rep 2012; 13:653 - 9; http://dx.doi.org/10.1038/embor.2012.75; PMID: 22653441
   PubMed Web of Science ®Google Scholar
• Ching YP, Leong VY, Wong CM, Kung HF. Identification of an autoinhibitory domain of p21-activated protein kinase 5. J Biol Chem 2003; 278:33621 - 4; http://dx.doi.org/10.1074/jbc.C300234200; PMID: 12860998
   PubMed Web of Science ®Google Scholar
• Deacon SW, Beeser A, Fukui JA, Rennefahrt UE, Myers C, Chernoff J, et al. An isoform-selective, small-molecule inhibitor targets the autoregulatory mechanism of p21-activated kinase. Chem Biol 2008; 15:322 - 31; http://dx.doi.org/10.1016/j.chembiol.2008.03.005; PMID: 18420139
   PubMed Web of Science ®Google Scholar
• Viaud J, Peterson JR. An allosteric kinase inhibitor binds the p21-activated kinase autoregulatory domain covalently. Mol Cancer Ther 2009; 8:2559 - 65; http://dx.doi.org/10.1158/1535-7163.MCT-09-0102; PMID: 19723886
   PubMed Web of Science ®Google Scholar
• Zhao ZS, Manser E, Chen XQ, Chong C, Leung T, Lim L. A conserved negative regulatory region in alphaPAK: inhibition of PAK kinases reveals their morphological roles downstream of Cdc42 and Rac1. Mol Cell Biol 1998; 18:2153 - 63; PMID: 9528787
   PubMed Web of Science ®Google Scholar
• Hashimoto H, Sudo T, Maruta H, Nishimura R. The direct PAK1 inhibitor, TAT-PAK18, blocks preferentially the growth of human ovarian cancer cell lines in which PAK1 is abnormally activated by autophosphorylation at Thr 423. Drug Discov Ther 2010; 4:1 - 4; PMID: 22491145
   PubMedGoogle Scholar
• Maruta H, He H, Tikoo A, Nur-e-Kamal M. Cytoskeletal tumor suppressors that block oncogenic RAS signaling. Ann N Y Acad Sci 1999; 886:48 - 57; http://dx.doi.org/10.1111/j.1749-6632.1999.tb09399.x; PMID: 10667202
   PubMed Web of Science ®Google Scholar
• Pecot CV, Calin GA, Coleman RL, Lopez-Berestein G, Sood AK. RNA interference in the clinic: challenges and future directions. Nat Rev Cancer 2011; 11:59 - 67; http://dx.doi.org/10.1038/nrc2966; PMID: 21160526
   PubMed Web of Science ®Google Scholar
• Yi C, Wilker EW, Yaffe MB, Stemmer-Rachamimov A, Kissil JL. Validation of the p21-activated kinases as targets for inhibition in neurofibromatosis type 2. Cancer Res 2008; 68:7932 - 7; http://dx.doi.org/10.1158/0008-5472.CAN-08-0866; PMID: 18829550
   PubMed Web of Science ®Google Scholar
• Bain J, Plater L, Elliott M, Shpiro N, Hastie CJ, McLauchlan H, et al. The selectivity of protein kinase inhibitors: a further update. Biochem J 2007; 408:297 - 315; http://dx.doi.org/10.1042/BJ20070797; PMID: 17850214
   PubMed Web of Science ®Google Scholar
• Kaneko M, Saito Y, Saito H, Matsumoto T, Matsuda Y, Vaught JL, et al. Neurotrophic 3,9-bis[(alkylthio)methyl]-and-bis(alkoxymethyl)-K-252a derivatives. J Med Chem 1997; 40:1863 - 9; http://dx.doi.org/10.1021/jm970031d; PMID: 9191963
   PubMed Web of Science ®Google Scholar
• Ghoreschi K, Laurence A, O'Shea JJ. Selectivity and therapeutic inhibition of kinases: to be or not to be?. Nat Immunol 2009; 10:356 - 60; http://dx.doi.org/10.1038/ni.1701; PMID: 19295632
   PubMed Web of Science ®Google Scholar
• Maroney AC, Finn JP, Connors TJ, Durkin JT, Angeles T, Gessner G, et al. Cep-1347 (KT7515), a semisynthetic inhibitor of the mixed lineage kinase family. J Biol Chem 2001; 276:25302 - 8; http://dx.doi.org/10.1074/jbc.M011601200; PMID: 11325962
   PubMed Web of Science ®Google Scholar
• Lin H, Yamashita DS, Xie R, Zeng J, Wang W, Leber J, et al. Tetrasubstituted pyridines as potent and selective AKT inhibitors: Reduced CYP450 and hERG inhibition of aminopyridines. Bioorg Med Chem Lett 2010; 20:684 - 8; http://dx.doi.org/10.1016/j.bmcl.2009.11.061; PMID: 20006500
   PubMed Web of Science ®Google Scholar
• Porchia LM, Guerra M, Wang YC, Zhang Y, Espinosa AV, Shinohara M, et al. 2-amino-N-4-[5-(2-phenanthrenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl]-phenyl acetamide (OSU-03012), a celecoxib derivative, directly targets p21-activated kinase. Mol Pharmacol 2007; 72:1124 - 31; http://dx.doi.org/10.1124/mol.107.037556; PMID: 17673571
   PubMed Web of Science ®Google Scholar
• Zhu J, Huang JW, Tseng PH, Yang YT, Fowble J, Shiau CW, et al. From the cyclooxygenase-2 inhibitor celecoxib to a novel class of 3-phosphoinositide-dependent protein kinase-1 inhibitors. Cancer Res 2004; 64:4309 - 18; http://dx.doi.org/10.1158/0008-5472.CAN-03-4063; PMID: 15205346
   PubMed Web of Science ®Google Scholar
• Maksimoska J, Feng L, Harms K, Yi C, Kissil J, Marmorstein R, et al. Targeting large kinase active site with rigid, bulky octahedral ruthenium complexes. J Am Chem Soc 2008; 130:15764 - 5; http://dx.doi.org/10.1021/ja805555a; PMID: 18973295
   PubMed Web of Science ®Google Scholar
• Feng L, Geisselbrecht Y, Blanck S, Wilbuer A, Atilla-Gokcumen GE, Filippakopoulos P, et al. Structurally sophisticated octahedral metal complexes as highly selective protein kinase inhibitors. J Am Chem Soc 2011; 133:5976 - 86; http://dx.doi.org/10.1021/ja1112996; PMID: 21446733
   PubMed Web of Science ®Google Scholar
• Murray BW, Guo C, Piraino J, Westwick JK, Zhang C, Lamerdin J, et al. Small-molecule p21-activated kinase inhibitor PF-3758309 is a potent inhibitor of oncogenic signaling and tumor growth. Proc Natl Acad Sci U S A 2010; 107:9446 - 51; http://dx.doi.org/10.1073/pnas.0911863107; PMID: 20439741
   PubMed Web of Science ®Google Scholar
• Guo C, McAlpine I, Zhang J, Knighton DD, Kephart S, Johnson MC, et al. Discovery of Pyrroloaminopyrazoles as novel PAK inhibitors. J Med Chem 2012; 55:4728 - 39; http://dx.doi.org/10.1021/jm300204j; PMID: 22554206
   PubMed Web of Science ®Google Scholar
• Zhang J, Wang J, Guo Q, Wang Y, Zhou Y, Peng H, et al. LCH-7749944, a novel and potent p21-activated kinase 4 inhibitor, suppresses proliferation and invasion in human gastric cancer cells. Cancer Lett 2012; 317:24 - 32; http://dx.doi.org/10.1016/j.canlet.2011.11.007; PMID: 22085492
   PubMed Web of Science ®Google Scholar
• Dummler B, Ohshiro K, Kumar R, Field J. Pak protein kinases and their role in cancer. Cancer Metastasis Rev 2009; 28:51 - 63; http://dx.doi.org/10.1007/s10555-008-9168-1; PMID: 19165420
   PubMed Web of Science ®Google Scholar
• Ong CC, Jubb AM, Zhou W, Haverty PM, Harris AL, Belvin M, et al. p21-activated kinase 1: PAK'ed with potential. Oncotarget 2011; 2:491 - 6; PMID: 21653999
   PubMedGoogle Scholar
• Molli PR, Li DQ, Murray BW, Rayala SK, Kumar R. PAK signaling in oncogenesis. Oncogene 2009; 28:2545 - 55; http://dx.doi.org/10.1038/onc.2009.119; PMID: 19465939
   PubMed Web of Science ®Google Scholar
• Knight ZA, Shokat KM. Features of selective kinase inhibitors. Chem Biol 2005; 12:621 - 37; http://dx.doi.org/10.1016/j.chembiol.2005.04.011; PMID: 15975507
   PubMed Web of Science ®Google Scholar